Third‑party trait markets normalize enhancement

Firms are already packaging raw embryo genotype data into off‑lab trait scores (IQ, height, ADHD risk), turning what clinics framed as health screening into a consumer market for enhancement‑relevant predictions. That creates a commercially distributed pathway to selection for non‑disease traits without centralized clinical oversight or consistent validation standards. — Commercial third‑party trait scoring short‑circuits clinical safeguards and will force urgent policy choices about disclosure, licensing, access, and whether to regulate trait predictions as medical diagnostics or consumer genomic products.